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Introduction: Cryopreserved saphenous vein allografts (Cryograft; CryoLife, Kennesaw, Ga) have been used as conduit in
infrainguinal revascularization when autogenous vein is inadequate or unavailable. Although some studies of Cryografts
report poor long-term patency, an anticoagulation protocol may improve outcome. We evaluated our experience with
Cryografts to further define their role in lower extremity revascularization.
Patients and Methods: Between March 1992 and March 2002, 240 infrainguinal revascularization procedures with
Cryografts were performed in 199 limbs of 177 patients. Eighty-nine percent of procedures were performed because of
ischemic rest pain or tissue loss, and 75% of vein grafts were implanted into infrapopliteal targets. Most patients received
anticoagulation therapy with warfarin sodium or aspirin, or both, postoperatively. Mean age of the cohort was 78 years;
61% were women; 75% had hypertension, 58% had diabetes, and 38% had renal dysfunction; and 47% were current or past
smokers.
Results: Mean follow-up was 7 months (range, 0-48 months). Primary patency rate was 83% at 1 month, 50% at 6 months,
30% at 12 months, and 18% at 24 months. Diabetes adversely affected graft patency. Warfarin sodium or antiplatelet
therapy did not significantly improve graft patency. Limb salvage was 80% at 1 year and 71% at 2 years.
Conclusions: Cryografts have low primary patency rates that are not affected by anticoagulation with warfarin sodium.
Short-term patency of these grafts may be sufficient to heal ischemic wounds and thereby prevent limb loss. However,
other less expensive alternatives, eg, prosthetic grafts with vein cuffs, are available and appear to have better patency.
Accordingly, use of Cryografts should be limited to revascularization through infected fields in patients without
autogenous conduit. (J Vasc Surg 2003;38:15-21.)
There is little doubt that autogenous greater saphenous
vein is the preferred conduit for infrainguinal revasculariza-
tion beyond the knee.1,2 In the absence of autogenous
greater saphenous vein, alternative autogenous conduits
such as arm vein,3 lesser saphenous vein,4 and composite
autogenous vein5 have been used with good results. As a
result of older patient age and the complexity of infraingui-
nal occlusive disease, adequate autogenous vein often is not
available, and an alternative conduit must be found.
Although prosthetic grafts have been used successfully
above the knee, they have been disappointing in infra-
geniculate bypass grafting.6,7 Distal modification of pros-
thetic grafts with vein cuffs and distal arteriovenous fistulas
has been shown to improve patency rates,8-10 but is cum-
bersome. Human umbilical vein was used for a time, but
has fallen out of favor because of late aneurysmal degener-
ation.11 Composite sequential reconstructions have shown
promise, but still require the presence of a segment of
usable autogenous vein.12
Given the absence of reliable conduit options for infra-
geniculate bypass grafting when suitable autogenous vein is
unavailable, the feasibility of venous allografts has been
studied.13 Development14 and standardization15 of cryo-
preservation techniques have stimulated interest in the use
of Cryografts (CryoLife, Kennesaw, Ga), which have the
advantage of ease of handling and “off the shelf” availabil-
ity. Although a number of clinical series using cryopre-
served vein allografts have been published,16-26 small sam-
ple size and contradictory findings have hampered their
interpretation. Over the past decade we have extensively
used Cryografts in infrainguinal revascularization, and
herein report our results.
METHODS
We retrospectively evaluated all infrainguinal bypass
procedures performed by the authors between March 1992
and March 2002 in which Cryografts were used. Office,
hospital, and electronic charts were reviewed after institu-
tional review board exemption status was granted. Epide-
miology, indication for procedure, and graft anastomosis
location were recorded. Comorbid conditions such as dia-
betes, hypertension, and current or past smoking were
noted. Renal dysfunction was defined as serum creatinine
concentration greater than 1.5 mg/dL or dialysis depen-
dence (Table I).
All patients underwent preoperative arteriography.
Vein mapping was routinely performed to outline and
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define the size and quality of autogenous vein. The decision
to use Cryograft as conduit was based on lack of autoge-
nous vein, inadequate autogenous vein, or surgeon prefer-
ence.
Cryografts were obtained at a cost of $4000 to $4500.
They were kept frozen in solution containing dimethyl
sulfoxide at 196°C until use. The Cryografts were sero-
matched for ABO/Rh blood grouping to the prospective
recipients. They were then thawed, rinsed, and prepared
according to the manufacturer’s instructions. All Cryo-
grafts were 3.5 mm or greater in diameter.
In the operating room, proximal and target vessels were
exposed, and 5000 U of heparin was administered before
proximal clamp placement. Activated clotting time was
measured and kept above 280 seconds. The Cryograft was
reversed and placed in a superficial tunnel. The distal anas-
tomosis was performed under tourniquet control. In 124
patients with 139 limbs (75%), warfarin sodium anticoag-
ulation therapy was started within the first 2 postoperative
days, with an international normalized ratio (INR) goal of
2.0-3.0. Therapeutic anticoagulation was achieved before
discharge from the hospital. Warfarin therapy was modu-
lated by the patients’ internal medicine physicians and was
continued until either graft failure or occurrence of an
anticoagulation-related complication. Fifty patients with
58 limbs (32%) were given postoperative aspirin or clopi-
dogrel. Thirty-seven patients with 42 limbs (21%) were
discharged with both warfarin and antiplatelet therapy.
Perioperative and postoperative complications that oc-
curred within 30 days of surgery were characterized as
systemic or local.27 Systemic complications included car-
diac events (myocardial infarction or sustained atrial or
ventricular arrhythmia), stroke, deep venous thrombosis,
and pulmonary embolism. Local complications included
wound infection, seroma, hemorrhage necessitating return
to the operating room, and graft thrombosis within 24
hours. Thirty-day mortality was calculated.
A follow-up visit with the vascular surgeon was sched-
uled during the first month after discharge and 3 to 6
months thereafter. Duplex ultrasound scanning or angiog-
raphy was ordered at the discretion of the vascular surgeon.
During follow-up, Cryograft patency was assessed, in ac-
cordance with Society for Vascular Surgery standards, at
physical examination performed by the vascular surgeon,
who evaluated for presence of a palpable graft pulse or
biphasic or triphasic Doppler waveform at two points over
the superficially placed graft.27 Suspected graft occlusion
was verified at duplex scanning. Routine Cryograft duplex
scanning was not performed during follow-up.
We defined two follow-up periods, one based on graft
patency, as evaluated by a vascular surgeon or diagnostic
test, and one based on limb salvage, as noted on office
records or computerized dictated hospital reports. This was
done because some patients were seen in the hospital by
another physician after loss to follow-up with the vascular
surgeon. Although graft patency could not be determined
by any physician but a vascular surgeon, the presence or
absence of the affected limb could be duly noted from any
physician’s dictated hospital report. Graft patency and limb
salvage actuarial life tables were calculated. Follow-up for
primary patency rate calculations ended when the graft was
confirmed to be thrombosed or last known to be patent,
whichever was shorter. Death and limb amputation were
other end points for termination of patency. Follow-up for
limb salvage rate calculation ended when the limb was
amputated, the patient died, or the patient was last known
to have the affected limb, on the basis of dictated reports
from the electronic chart.
Graft patency and limb salvage rates at each time point
for the 199 primary Cryografts were calculated with the life
table method, as outlined by the Society of Vascular Sur-
gery Ad Hoc Committee on Reporting Standards.27 Mean
values are reported, with standard error of the mean. All life
table graphs shown have standard error less than 10%. The
Cox multivariate regression model with forward selection
was used to assess the influence on graft patency and limb
salvage of gender, age less than 75 years, comorbid condi-
tions (diabetes, smoking, hypertension, renal dysfunction),
indication for surgery (rest pain, tissue loss), history of
bypass grafting, and site of distal anastomosis (below-knee
popliteal or tibial). Life table differences were analyzed with
the log-rank test (Statistical Analysis System version 8.4;
SAS, Cary, NC).
Patients. During the 10-year study 240 Cryografts
were implanted into 199 limbs of 177 patients. This repre-
sents 19% of all infrainguinal bypass grafting performed by
the authors during that period. Mean patient age at primary
graft implantation was 78 years (range, 43-96 years). De-
mographic data for the 177 patients are shown in Table I.
Fifty percent of the 199 limbs evaluated had not undergone
previous infrainguinal bypass procedures; 27% had under-
gone one such procedure, and 21% had undergone two or
more procedures. Eighty-nine percent of these procedures
were performed because of tissue loss or rest pain (Fig 1).
The common femoral artery was the most common site of
inflow, and tibial vessels were the most common site of
distal anastomosis (Table II).
One hundred twenty-seven additional procedures were
performed after primary Cryograft placement (Fig 2). Thir-
ty-five procedures were performed on failing Cryografts to
maintain primary assisted patency; 17 procedures were
performed on thrombosed grafts to restore secondary pa-
tency; and 75 new bypass grafts were placed after the
primary Cryograft failed. Graft aneurysm rate was defined
Table I. Demographic data for 177 patients
Characteristic n %
Male 69 39
Female 108 61
Diabetes 102 58
Tobacco use 80 47
Hypertension 130 75
Renal dysfunction 66 38
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by the number of aneurysms formed divided by the number
of grafts patent.
RESULTS
Thirty-day mortality was 6%. In 7 of 11 patients who
died within 30 days, death was secondary to a cardiac event.
Overall morbidity for the 240 Cryograft revascularization
procedures was 22%. Systemic complications included car-
diac events (6%), pulmonary embolism (0.5%), deep venous
thrombosis (0.5%), and stroke (0.5%). Local complications
included wound infection (5%), seroma (1%), hemorrhage
that necessitated return to the operating room (3%), and
graft thrombosis within 24 hours (5%). Seventy-two per-
cent of patients were alive at 1 year, and 69% of patients
were alive at 2 years.
Follow-up to assess mean graft patency of the 199
primary grafts was at 7  1 month. The primary patency
rate for the cohort was 83% at 1 month, 50% at 6 months,
30% at 12 months, and 18% at 24 months (Fig 3). The
primary patency of Cryografts to below-knee popliteal tar-
gets was 87% at 1 month and 61% at 6 months. Primary
patency for Cryografts to infrapopliteal target vessels was
81% at 1 month, 49% at 6 months, 26% at 12 months, and
15% at 24 months (Fig 4). There was no statistically signif-
icant difference between below-knee and infrapopliteal
Cryograft primary patency rates.
Thirty-one procedures were performed on 25 failing
primary grafts to maintain primary assisted patency, which
was 84% at 1 month, 53% at 6 months, 32% at 12 months,
and 22% at 2 years. Fifteen procedures were performed on
14 thrombosed grafts to maintain secondary patency,
which was 83% at 1 month, 52% at 6 months, 30% at 12
months, and 20% at 24 months. The difference between
primary, primary assisted, and secondary patency rates was
not statistically significant (log-rank test). At multivariate
analysis, diabetes was the only factor independently associ-
ated with worse primary patency (P  .02; Cox regression
analysis; Fig 5). Warfarin sodium, antiplatelet agent, or a
combination of the two, did not have a statistically signifi-
cant effect on primary graft patency in any treatment group
(log-rank test).
In nine primary Cryografts aneurysmal degeneration
developed, and all were repaired with interposition grafts.
Mean time to aneurysm diagnosis was 21  5 months
(range, 4-46 months). Because of low graft patency at 2
years, aneurysmal degeneration rate was high at 44%. Two
graft aneurysms ruptured, necessitating emergent repair.
Mean limb salvage follow-up was 14 1 months. Limb
salvage rate was 93% at 1 month, 88% at 6 months, 80% at
12 months, and 71% at 24 months (Fig 6). Multivariate
analysis revealed that limb salvage rate was higher in limbs
that underwent femoral to below-knee popliteal bypass
grafting, as compared with those with femoral to infrapop-
liteal bypass grafts. This difference was statistically signifi-
cant (P  .054, Cox regression analysis; P  .05, log-rank
test; Fig 7).
The primary patency rate for the 41 secondary Cryo-
grafts was 85% at 1 month, 54% at 6 months, 17% at 12
months, and 8% at 24 months. Limb salvage rates for those
limbs that received a secondary Cryograft or autogenous
bypass graft was 100% at 6 months and 95% at 1 year.
Within the first year the limb salvage rate was better in
patients who received a secondary Cryograft or autogenous
vein graft. However, this trend was not statistically signifi-
cant (log-rank test).
DISCUSSION
This study represents the largest reported experience
with Cryografts. Use of Cryografts is attractive. The con-
duit is available “off the shelf” and has the physical appear-
ance and handling of autogenous saphenous vein. Further-
more, its use foregoes the time and effort necessary to
harvest and splice segments of alternative autogenous vein.
It has potential to be the vascular surgeon’s “dream con-
duit.”
Initially, we used Cryografts not only when autogenous
saphenous vein was unavailable or inadequate, but also in
lieu of alternative autogenous vein. This explains in part our
high percentage (50%) of limbs without previous bypass
procedures. Over time, problems with Cryografts emerged,
and our initial enthusiasm was replaced with cautious prag-
matism. The purpose of this report is to evaluate our
extensive experience with Cryografts and determine their
role in the armamentarium of today’s vascular surgeon.
Our cohort of 177 patients differs from that in other
published studies of infrainguinal bypass grafting. With a
mean age of 78 years, our patients were older than those in
other large series.1-3,5,10,12,22 The preponderance of
women, 61% of our patients, also separates our group from
other studies. More than a third of our patients had sub-
stantial renal dysfunction. Finally, the cumulative 1-year
survival rate in our cohort was only 72%, which is lower
than that reported in other series.3,7 Our group of patients
clearly falls into the more terminally ill portion of the
spectrum, and this likely explains our relatively high 30-day
mortality rate of 6%.
Evaluation of these grafts reveals poor 1-year primary
patency of 30%; however, this result is similar to the 37%
1-year patency rate reported by Martin et al.22 in the largest
published series of Cryografts (Table III). Although others
have reported higher Cryograft primary patency rates, in-
terpretation of those results must be tempered by the small
Fig 1. Indications for 199 primary revascularization procedures
with Cryografts.
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number of grafts evaluated.18,25 Our 1-year primary pa-
tency rate for Cryografts to infrapopliteal target vessels of
26% (Fig 4) is in the 21% to 48% primary patency rate
reported for polytetrafluoroethylene (PTFE) grafts used in
infrapopliteal position.6,7 Furthermore, it is significantly
less than the primary patency rate of 82% reported for
infrapopliteal PTFE grafts modified with distal interposi-
tion vein cuffs.9
In a prospective trial of Cryografts in 24 patients,
Buckley et al16 reported an impressive 87% 1- year primary
patency rate. These results are attributed to an anticoagu-
lation protocol consisting of preoperative aspirin, perioper-
ative low-dose heparin and dextran, and postoperative war-
farin, aspirin, and dipyridamole. Of note, 42% of grafts in
that series had distal anastamotic modification with either
Table II. Site of proximal and distal anastomosis in 199 primary cryograft revascularization procedures
Distal anastomosis
Proximal anastomosis
EIA CFA SFA PFA AKP PRG Total
n % n % n % n % n % n % n %
AKP 0 0 1 0 0 0 1 .05
BKP 5 22 3 0 0 11 41 21
Tibial 9 77 17 2 1 21 127 64
TPT 0 2 0 0 0 1 3 2
Pedal 0 7 7 0 2 2 18 9
PRG 2 3 1 1 0 2 9 4
Total 16 8 111 56 29 15 3 1 3 1 37 19 199 100
EIA, External iliac artery; CFA, common femoral artery; SFA, superficial femoral artery; PFA, profunda femoral artery; AKP, above-knee popliteal artery; BKP,
below-knee popliteal artery; PRG, previous graft; Tibial, anterior tibial, posterior tibial, peroneal arteries; TPT, tibioperoneal trunk.
Fig 2. Categorization of 127 secondary procedures after primary
revascularization with Cryografts. TPA, Tissue plasminogen acti-
vator.
Fig 3. Primary patency curve and life table for 199 primary
revascularization procedures with Cryografts.
Fig 4. Comparison of primary patency rates in grafts with below-
knee popliteal (black line) and infrapopliteal (gray line) distal
anastomosis (P  NS; Cox multivariate regression analysis).
Fig 5. Effect of diabetes on primary Cryograft patency (P  .05;
log-rank test). Gray line, Diabetes; black line, no diabetes.
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vein cuffs or arteriovenous fistulas. In our series, 75% of
patients were given warfarin sodium and 32% were given an
antiplatelet agent; 21% of patients received both warfarin
and antiplatelet therapy. Warfarin or antiplatelet therapy
did not have a statistically significant effect on Cryograft
patency in our series or other series.17,20,22,26 In our series,
administration of both warfarin and antiplatelet therapy did
not improve graft patency. This finding differs from the
high Cryograft patency rate achieved with combination
therapy with warfarin sodium and aspirin in the prospective
series by Buckley et al.16 A limitation of our study is that the
exact degree of anticoagulation over follow-up is not
known for each individual patient; however, this limitation
is present in most other retrospective Cryograft series.19-
22,25,26
Although early graft failure in autogenous and pros-
thetic reconstruction procedures is usually due to myointi-
mal hyperplasia, most Cryograft failures are due to allograft
rejection.17,28 Even though this has not been assessed in
our study, allograft rejection involving both cell-mediated
and humoral immune response has a role in graft fail-
ure.17,28 The result is irreversible endothelial loss and pro-
gressive medial fibrosis and degeneration.15 There is some
controversy regarding the effect of the cryopreservation
process itself on endothelial layer integrity. Nevertheless,
there is evidence that the overall anatomy and fibrinolytic
capacity of appropriately cryopreserved veins is main-
tained.15
Attempts to diminish the allograft rejection process in
Cryografts with immunosuppression therapy had some suc-
cess in a canine model.29 However, use of azathioprine in a
clinical trial was not successful.16 Other immunosuppres-
sive protocols may be effective; however, potential serious
side effects of therapy may not justify clinical trials in this
patient population. Although anticoagulation protocols
may, in theory, improve Cryograft patency, it is unlikely
that their effect alone is significant in the setting of allograft
rejection that affects most of these grafts.
Secondary procedures for failing or failed Cryografts
were uncommon in our group, and their success rate was
low; primary assisted and secondary patency rates did not
significantly differ from primary patency rates. The poor
primary assisted patency rate explains our practice of not
following up with routine duplex scanning. Our findings
with regard to primary assisted patency and secondary
patency are consistent with results reported by Martin et
al,22 but vary with findings of Walker et al.26 In the latter
series, the authors took an aggressive posture toward Cryo-
graft thrombectomy and revision. Although almost half of
their grafts could not be reopened, they were able to
increase their 1-year cumulative secondary patency rate
from 28% to 46%.
At logistic regression analysis only diabetes negatively
affected Cryograft patency (Fig 5). Although previous by-
pass procedures25 influence Cryograft patency rates, diabe-
tes has not been previously reported to do so. There are
conflicting reports that diabetes negatively30 and positive-
ly1,31 affects infrainguinal autogenous vein bypass patency.
Cryografts that remain open for a prolonged period are
prone to aneurysmal degeneration. In our series, aneurys-
mal degeneration developed in 9 grafts, for a 2-year aneu-
rysm incidence of 44%. In the series by Martin et al,22
aneurysmal degeneration developed 6 of 115 Cryografts,
for an approximately 25% aneurysm formation rate at 21⁄2
years. Aneurysmal degeneration affects other biologic
grafts, and has been reported in 33% of human umbilical
vein grafts at 2 years.11
Despite low Cryograft patency, limb salvage in our
group of patients was 71% at 2 years, similar to the results
reported by Martin et al22 and Harris et al19 (Table III).
Our relatively high limb salvage rate in the face of low graft
patency can be explained in part by the 41 secondary
Cryografts and 24 secondary autogenous grafts that were
placed after primary Cryograft failure. There was a trend
toward a higher limb salvage rate in patients who under-
went secondary bypass procedures, although it fell short of
statistical significance. Repetitive bypass grafting signifi-
cantly extends limb salvage.32 Another possibility to ex-
plain our high limb salvage rate is that Cryografts, while
patent, enabled healing of lower extremity ulcerations in a
large proportion of our patients. Ulcers may not have
Fig 6. Limb salvage curve and life table for 199 limbs after primary
Cryograft revascularization.
Fig 7. Effect of below-knee popliteal (black line) and infrapopli-
teal (gray line) distal Cryograft anastamosis on limb salvage (P 
.05; log-rank test).
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recurred despite graft failure. This hypothesis cannot be
proved in our series or in any study that does not prospec-
tively surveil ulcer healing along with limb salvage. Limb
salvage in excess of graft patency has been described in
PTFE grafts6 and human umbilical artery grafts.11
Duration and completeness of follow-up are admitted
weaknesses of this study. Mean follow-up for graft patency
of 7 months and for limb salvage of 11 months is relatively
short; however, it is within the follow-up range of 5 to 21
months reported in other Cryograft series.18,20,22-26 We
propose several reasons to explain our relatively high pa-
tient loss to follow-up. With mean age of 78 years, our
patient cohort was older than patients in many other stud-
ies. Many of these patients were not in independent living
situations, and because of social and economic reasons they
could not comply with follow-up. Furthermore, given our
tertiary care setting, many of our patients were referred
from communities outside our metropolitan area; these
patients returned to their local communities for follow-up.
Our decade-long experience with Cryografts has
taught us some important lessons. Although Cryografts
look, feel, and handle like autogenous vein, they are far
from being the holy grail of infrainguinal reconstruction.
Despite an acceptable early primary graft patency rate,
Cryografts have poor midterm patency. Primary patency is
worse in patients with diabetes, and is not significantly
affected by warfarin therapy. Although we do not negate
the excellent results noted by Buckley et al,16 who used an
extensive anticoagulation protocol, given the immunologic
mechanism of Cryograft failure, we are skeptical that anti-
coagulation alone is sufficient to prevent graft occlusion.
Those grafts that do remain open for extended periods have
a significant rate of aneurysm formation. Secondary proce-
dures on failing or failed grafts do not provide significantly
improved patency. Cryografts may affect definitive ulcer
healing despite early occlusion. In addition, a policy of
repetitive Cryograft bypass grafting may enable improved
limb salvage. However, similar or better results may be
obtained with a more cost-effective conduit, eg, PTFE
grafts, with or without distal graft modification. All of these
issues have been recently overshadowed by the US Food
and Drug Administration order to retain all Cryografts
processed by Cryolife, a major supplier of the grafts, be-
cause of concern about infectious disease prevention pro-
cedures.33
We have significantly narrowed our indications for
Cryograft use. Cryografts may be justified in revasculariza-
tion procedures through infected fields when autogenous
conduit is not available or adequate. In that clinical setting,
use of this graft is adequate.18 Otherwise, PTFE grafts
should be considered for use in this difficult patient popu-
lation.
We thank Meenu Sandhu, MS, of the Department of
Biostatistics, Cedars-Sinai Medical Center, for assistance
with statistical analysis.
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